摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

5-Tert-butyl-1,3-benzoxathiole

中文名称
——
中文别名
——
英文名称
5-Tert-butyl-1,3-benzoxathiole
英文别名
5-tert-butyl-1,3-benzoxathiole
5-Tert-butyl-1,3-benzoxathiole化学式
CAS
——
化学式
C11H14OS
mdl
——
分子量
194.3
InChiKey
VJTAOMPQOZLAES-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.9
  • 重原子数:
    13
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.45
  • 拓扑面积:
    34.5
  • 氢给体数:
    0
  • 氢受体数:
    2

文献信息

  • C-ARYL GLUCOSIDE DERIVATIVE, PREPARATION METHODS THEREOF, AND MEDICAL APPLICATIONS THEREOF
    申请人:JIANGSU HANSOH PHARMACEUTICAL GROUP CO., LTD.
    公开号:US20160222047A1
    公开(公告)日:2016-08-04
    C-aryl glucoside derivatives, preparation methods thereof, and medical applications thereof are described. Specifically, compounds represented by formula I, and, tautomers, enantiomers, diastereomers, racemates, and pharmaceutically acceptable salts of the compounds, preparation methods thereof, pharmaceutical compositions containing the compounds, and applications thereof are described. Compounds of formula (I) are useful as therapeutic agents, and particularly as sodium-dependent glucose contransporter protein (SGLT) inhibitors.
    本文描述了C-芳基葡萄糖苷衍生物,其制备方法以及医药应用。具体而言,描述了由式I表示的化合物,以及该化合物的互变异构体、对映体、非对映体、拉卡酯和药学上可接受的盐,其制备方法,含有该化合物的药物组合物以及其应用。式(I)的化合物可用作治疗剂,特别是作为依赖葡萄糖共转运蛋白(SGLT)抑制剂
  • METHOD FOR PRODUCING DIPHENYLMETHANE DERIVATIVE
    申请人:DAEWOONG PHARMACEUTICAL CO., LTD.
    公开号:US20190169174A1
    公开(公告)日:2019-06-06
    The present invention relates to an improved method for producing a diphenylmethane derivative which is effective as a sodium-dependent glucose cotransporter (SGLT) inhibitor, the method being carried out by means of a convergent synthesis method in which each major group is separately synthesized and then coupled. As such, in comparison to a linear synthesis method disclosed in existing documents, the synthesis pathway is compact and yield can be increased, and risk factors inherent in the linear synthesis pathway can be reduced. Furthermore, the crystal form of the compound produced according to the method has superb physicochemical characteristics, and thus can be effectively utilized in fields such as pharmaceutical manufacturing.
    本发明涉及一种改进的制备二苯甲烷生物的方法,该方法作为一种依赖型葡萄糖共转运蛋白(SGLT)抑制剂具有高效性,该方法通过收敛合成方法进行,其中每个主要基团分别合成然后耦合。因此,与现有文件披露的线性合成方法相比,合成途径更为紧凑,产率可以提高,并且线性合成途径固有的风险因素可以降低。此外,根据该方法生产的化合物的晶型具有出色的物理化学特性,因此可以有效地应用于制药制造等领域。
  • NOVEL DIPHENYLMETHANE DERIVATIVES AS SGLT2 INHIBITORS
    申请人:Choi Soongyu
    公开号:US20140088079A1
    公开(公告)日:2014-03-27
    The present invention relates to a compound with a diphenylmethane moiety having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes. The present invention also provides a method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound.
    本发明涉及一种具有二苯甲烷基团的化合物,其具有对存在于肠和肾中的依赖性葡萄糖共转运体2(SGLT2)的抑制活性,以及包含该化合物作为活性成分的制药组合物,用于预防或治疗代谢性疾病,尤其是糖尿病。本发明还提供了一种制备该化合物的方法,以及使用该化合物预防或治疗代谢性疾病,尤其是糖尿病的方法。
  • NOVEL C-ARYL ANSA SGLT2 INHIBITORS
    申请人:Kim Min Ju
    公开号:US20140213642A1
    公开(公告)日:2014-07-31
    Disclosed is a novel C-aryl ansa compound having an inhibitory activity against sodium-dependent glucose cotransporter 2 (SGLT2) being present in the intestine and kidney, and a pharmaceutical composition comprising the same as an active ingredient, which is useful for preventing or treating metabolic disorders, particularly diabetes. Also provided are a method for preparing the compound, and a method for preventing or treating metabolic disorders, particularly diabetes, by using the compound.
    本发明涉及一种新的C-芳基ansa化合物,具有抑制肠和肾中存在的依赖性葡萄糖转运蛋白2(SGLT2)的活性,以及包含该化合物作为活性成分的制药组合物,该组合物对预防或治疗代谢紊乱,特别是糖尿病有用。还提供了一种制备该化合物的方法以及使用该化合物预防或治疗代谢紊乱,特别是糖尿病的方法。
  • Amine Derivatives as Potassium Channel Blockers
    申请人:Harvey Andrew
    公开号:US20140336198A1
    公开(公告)日:2014-11-13
    The present invention relates to compounds useful in the modulation of potassium channel activity in cells, in particular the activity of Kv1.3 channels found in T cells. The invention also relates to the use of these compounds in the treatment or prevention of autoimmune and inflammatory diseases, including multiple sclerosis, pharmaceutical compositions containing these compounds and methods for their preparation.
    本发明涉及用于调节细胞中通道活性的化合物,特别是用于调节T细胞中发现的Kv1.3通道活性的化合物。本发明还涉及使用这些化合物治疗或预防自身免疫和炎症性疾病,包括多发性硬化症,含有这些化合物的制药组合物以及它们的制备方法。
查看更多

同类化合物

四碘-2-磺基苯酸酐 四溴-2-磺基苯甲酸环酐 N,N'-二[[(1,3-苯并氧硫杂环戊烷-2-基)硫代]甲基]脲 5-羟基-4,6,7-三甲基-2-丙基-1,3-苯并氧杂噻唑 3-(5-羟基-4,6,7-三甲基-1,3-苯并氧杂噻唑-2-基)丙醇 2-磺基苯甲酸酐 2-(2-甲氧基丙烷-2-基)-7,7-二甲基-4-叔-丁基-8-氧杂-9-硫杂双环[4.3.0]壬-2,4,10-三烯 1,3-苯并噁噻唑,5-甲氧基-,3,3-二氧化 3-ethoxycarbonyl-2-methyl-5-(2',3'-O-sulfonyl-β-D-erythrofuranosyl)furan 2-Isopropyloxy-2-n-pentyl-1,3-benzoxathiol 5-nitrospiro[1,3-benzoxathiole-2,1'-cyclohexane] 2-ethyl-5-hydroxy-4,6,7-trimethyl-1,3-benzoxathiole 4-methyl-2-sulfo-benzoic acid-anhydride 2-heptyl-5-hydroxy-4,6,7-trimethyl-1,3-benzoxathiole 2-butyl-5-hydroxy-4,6,7-trimethyl-1,3-benzoxathiole 2-hexyl-5-hydroxy-4,6,7-trimethyl-1,3-benzoxathiole 1,1-dichloro-3,3-bis(trifluoromethyl)-5-methyl-2,1(3H)-benzoxathiole 4-(2-Cyclohexyl-benzo[1,3]dithiol-2-yl)-2-(2-p-tolyl-benzo[1,3]oxathiol-2-yl)-1H-pyrrole 2-Methoxy-4,5-methylenethiooxyamphetamine 2-Nonyl-benzo[1,3]oxathiole 2-t-Butyloxy-2-t-butyl-1,3-benzoxathiol 6-tert-Butyl-2-methyl-4-oxo-4H-3,1-benzoxathiin-8-carboxamid tert-butyl (3-((6-acetylbenzo[d][1,3]oxathiol-5-yl)oxy)propyl)carbamate 5-(4-fluoro-3-methylphenyl)-2,2-dimethyl-4H-benzo[d][1,3]oxathiin-4-one 2,10-dimethyl-dibenz[c,e][1,2,7]oxadithiepin-5,5,7,7-tetraoxide 8-Trimethylsilyl-2,2,6,6-tetramethylbenzo[1,2-d:5,4-d']-bis(1,3)oxathiole 5-fluoro7-(2-chloro-phenyl)-benzo[1,3]oxathiole-2,2-dicarboxylic acid diethyl ester 1-(2,3,7,8-Tetrahydro-benzo[1,2-b;4,5-b']bis[1,4]dithiin-5-yl)-ethanone 1,1-Dioxo-5-propoxy-1H-1λ6-benzo[c][1,2]oxathiol-3-one 7-<1-methyl-1-(trimethylamonio)ethyl>-3,3-dimethyl-3H-2,1-benzoxiathiole 1,1-dioxide fluorosulfonate 3-(5-methoxymethoxy-4,6,7-trimethyl-1,3-benzoxathiole-2-yl)propanol Benzo<1,2-c:5,4-c'>1,2,6,7-diisooxathiol-3,5-dion-1,1,7,7-tetroxid 2,3,4,5,7,8-Hexachlorbicyclo<4.2.0>octa-1,3,5-trien-7,8-diylsulfat 4-methyl-3,3-bis(trifluoromethyl)-3',3'-dimethyl-1,1'-spiro<3H-2,1-benzoxathiole> 5,7-diisopropyl-3,3-dimethylbenz-2,1-oxathiole 1-oxide 6-fluoro-5-methoxy-1,3-benzoxathiole 3,3-dioxide 3-ethoxycarbonyl-2-methyl-5-(2',3'-O-sulfonyl-α-D-erythrofuranosyl)furan 5-Isopropoxy-1,1-dioxo-1H-1λ6-benzo[c][1,2]oxathiol-3-one 1,3-Benzoxathiol-essigsaeure-(2)-methylester 2-Hydroxy-3-methyl-benzo-1,4-oxathien 4-(5-chloro-1,4-benzoxathian-8-oyl)-5-cyclopropylisoxazole S-oxide 5-Chlor-1,3-benzoxathiol 3-(3-benzyloxy-4-methoxyphenyl)-2,3-dihydro-1,4-benzoxathiine 2-(2-Cyclohexyl-benzo[1,3]oxathiol-2-yl)-1-methyl-1H-pyrrole 2,2'-spirobi(1,3-benzoxathiole) 1-(2-phenyl-benzo[1,3]oxathiol-2-yl)-propan-2-ol 2-Methyl-benzo-1,4-oxathiadien